This is a summary of the European public assessment report (EPAR) for Parsabiv. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Parsabiv. For practical information about using Parsabiv, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
Therapeutic Area (MeSH)
ATC Code
H05BX04
ATC Item
etelcalcetide
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| etelcalcetide hydrochloride | N/A | 依特卡肽 |
EMA Name
Parsabiv
Medicine Name
Parsabiv
Aliases
N/A
